Aligos Therapeutics, Inc. SEC filings ALGS
Aligos Therapeutics, Inc. has 348 filings in SEC EDGAR's recent list, going back to Jan 16, 2020. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 6, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 6, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 3, 2025 | — |
| CORRESP | Letter to the SEC | Apr 1, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2025 | — |
| D | Filing | Feb 28, 2025 | — |
| EFFECT | Filing | Nov 18, 2024 | — |
| CORRESP | Letter to the SEC | Nov 14, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 13, 2024 | — |
| SC TO-I/A | Filing | Feb 28, 2024 | — |
| SC TO-I | Filing | Jan 30, 2024 | — |
| SC TO-C | Filing | Jan 25, 2024 | — |
| EFFECT | Filing | Nov 27, 2023 | — |
| CORRESP | Letter to the SEC | Nov 22, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2023 | — |
| D | Filing | Nov 7, 2023 | — |
| DEFR14A | Filing | Jun 2, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 27, 2022 | — |
| CORRESP | Letter to the SEC | Dec 22, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 8, 2022 | — |
| EFFECT | Filing | Nov 19, 2021 | — |
| CORRESP | Letter to the SEC | Nov 17, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2021 | — |
| EFFECT | Filing | Jun 30, 2021 | — |
| CORRESP | Letter to the SEC | Jun 28, 2021 | — |
| CORRESP | Letter to the SEC | Jun 28, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2021 | — |
| DRS | Filing | Jun 4, 2021 | — |
| EFFECT | Filing | Oct 15, 2020 | — |
| CERT | Filing | Oct 14, 2020 | — |
| CORRESP | Letter to the SEC | Oct 13, 2020 | — |
| CORRESP | Letter to the SEC | Oct 13, 2020 | — |
| 8-A12B | Filing | Oct 13, 2020 | — |
| SEC STAFF LETTER | Filing | Oct 5, 2020 | — |
| CORRESP | Letter to the SEC | Oct 2, 2020 | — |
| SEC STAFF LETTER | Filing | Sep 28, 2020 | — |
| CORRESP | Letter to the SEC | Sep 25, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2020 | — |
| DRS | Filing | Aug 26, 2020 | — |
| D | Filing | Jan 16, 2020 | — |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ALGS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1799448
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.